Navigation Links
Sorrento Therapeutics' Innovative Approach to Developing Vaccines and Therapeutics for MRSA Receives Continued Support From the National Institute of Allergy and Infectious Diseases
Date:7/1/2011

SAN DIEGO, July 1, 2011 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC Bulletin Board: SRNE) today announced that it has received an Advanced Technology Small Business Technology Transfer Research (STTR) grant from the National Institute of Allergy and Infectious Diseases. The peer-reviewed grant was awarded  in further support of the Company's program to generate and develop novel antibody therapeutics and vaccines to combat Staphylococcus aureus (S. aureus or "Staph") infections, including methicillin-resistant S. aureus (MRSA), by disrupting quorum sensing, a bacterial communication process essential to virulence. The Phase I grant award is for a total of $600,000, $300,000 annually for two years, with the possibility of Phase II funding of $1 million per year for up to 3 years. $300,000 was previously funded in 2010 and this second grant award represents year two of the Phase I grant award.  In recommending the grant application for funding, expert panel reviewers noted that targeting quorum sensing and the virulence factors of S. aureus represented a paradigm shift, which could result in fewer side effects than conventional drug therapies.

"In view of this second grant award, it is clear that the NIH remains highly motivated to fund the innovative approach of quorum quenching we licensed from The Scripps Research Institute (TSRI) to tackle the serious healthcare burden of Staph aureus infections," said Henry Ji, Ph.D., Interim Chief Executive Officer and Chief Scientific Officer of Sorrento Therapeutics.

Sorrento Therapeutics' MRSA program targets specific auto-inducing peptides (AIPs) central to the quorum sensing system of S. aureus, which induces bacterial virulence. Masking these AIPs leads to a disruption of bacterial communication ("quorum quenching") and suppresses virulence. In January of 2010,
'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sorrento Therapeutics, Inc. and QuikByte Software, Inc. Complete Merger
2. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
3. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
4. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
5. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
6. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
7. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
8. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
9. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
10. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
11. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2015)... ... July 26, 2015 , ... Maine Standards ... verification / linearity test kit. The VALIDATE® ANEMIA kit contains Ferritin, Folate, and ... prepared using the CLSI recommended “equal delta” method for linearity testing and is ...
(Date:7/24/2015)... , July 24, 2015 Ryan & ... filed in United States District Court for the Northern District ... persons or entities that purchased the common stock of Avalanche ... between July 31, 2014 and June 15, 2015, inclusive (the ... September 8, 2015, move the Court for appointment as a ...
(Date:7/24/2015)... July 24, 2015 Equity Research ... BioPharma Inc. (NASDAQ: PDLI ), Arena Pharmaceuticals Inc. ... ), Northwest Biotherapeutics Inc. (NASDAQ: NWBO ), and ... report on PDL BioPharma can be accessed at ... Composite ended at 5,146.41, down 0.49%, the Dow Jones ...
(Date:7/24/2015)... 2015 Orexigen Therapeutics, Inc. (Nasdaq: OREX ... second quarter 2015 on Thursday, August 6 before the ... business update and discuss the financial results in a ... Time (5:00 a.m. Pacific Time). The live ... 447-0521 (domestic) or (847) 413-3238 (international), participant code 40327229. ...
Breaking Biology Technology:Maine Standards Company, LLC Announces Release of VALIDATE® ANEMIA Calibration Verification / Linearity Test Kit 2Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 2Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 3Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 2Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 3Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 4Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 5
... PARK, N.C., April 14, 2011 Talecris Biotherapeutics Holdings Corp. ... earnings release after the market closes on April 27, 2011. ... not be hosting a conference call to discuss its first ... Inspiration. Dedication. Innovation. Talecris Biotherapeutics ...
... NEW YORK, April 14, 2011 ... research report is available in its ... Market: DNA Probes And Biochips ... New Product Development Opportunities and ...
... at Penn State University, the Salk Institute for Biological ... recreating a schizophrenic patient,s own brain cells, which then ... dish. The method brings researchers a step closer to ... is expected to be used to study other mysterious ...
Cached Biology Technology:Reportlinker Adds Molecular Diagnostics Market: DNA Probes And Biochips 2Reportlinker Adds Molecular Diagnostics Market: DNA Probes And Biochips 3Scientists recreate brain cells from skin cells to study schizophrenia safely 2Scientists recreate brain cells from skin cells to study schizophrenia safely 3
(Date:6/30/2015)... June 30, 2015 Genisphere announced ... CEO to help further develop Genisphere,s therapeutics capabilities and ... experience, having spent much of the last 25 years ... Baxter Bioscience, and Johnson & Johnson. Tom started his ... and Biotech Corporate Finance. He graduated from Dartmouth College ...
(Date:6/26/2015)... 2015 ATL Technology, LLC, a top provider of ... single use solutions, headquartered in Springville, Utah ... California corporation with locations in ... Costa Rica ). This acquisition will incorporate ... with ATL Technology,s existing facility in Costa Rica ...
(Date:6/25/2015)...  Imagine a tool specifically designed to help you ... That,s exactly what USANA,s True Health Assessment ... health program provides a personalized approached to measuring your ... lifestyle and nutrition. At the Canadian ... USANA,s THA was honored with the Industry Innovation Award. ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2
... dinosaurs died and became fossilized, soft tissues didn't ... through a gradual replacement of all organic material ... State University paleontologist, however, could literally turn that ... professor of paleontology with a joint appointment at ...
... ATP (or GTP, a related energy currency) and transform ... myosin and dynein, proteins that use ATP to ferry ... proteins. The ATP-dependent assembly of actin or tubulin fibers ... march of white blood cells toward pathogens is powered ...
... Ph.D., Senior Bioinformatics Scientist at the European Molecular Biology ... they have identified a new primate-specific gene family that ... eight family members, the RGP gene cluster may help ... from the rest of the animal kingdom. , , ...
Cached Biology News:NC State scientist finds soft tissue in T. rex bones 2DNA Recombination and Repair—A New Twist to RecA Function 2Scientists document complex genomic events leading to the birth of new genes 2Scientists document complex genomic events leading to the birth of new genes 3
kismet (dK-20)...
... Thermo Hybaid's unique Electro-4 design allows ... the Electro-4 it is possible to run ... tank, by stacking up to four,horizontal gels. ... adjustable according to the number of gels ...
Lyophilized. Purity: ≥90% by electrophoresis. Reconstitute in 0.3% NaCl. Prepared from serum that has been shown by certified tests to be negative for HBsAg and for HIV and HCV antibodies. ...
p230 trans Golgi Purified Anti-Human clone 15, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
Biology Products: